Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure

P. Mease, A. Deodhar, R. Fleischmann, J. Wollenhaupt, D. Gladman, P. Leszczyński, P. Vitek, A. Turkiewicz, M. Khraishi, O. FitzGerald, R. Landewé, M. De Longueville, B. Hoepken, L. Peterson, D. Van Der Heijde

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Fingerprint

Dive into the research topics of 'Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure'. Together they form a unique fingerprint.

Medicine & Life Sciences